BioWorld

Feb. 11, 2004

CuraGen Planning To Pull Down $75M In Convertibles Placement

CuraGen Corp. said it plans to offer $75 million in convertible notes due 2011 in a private placement, with an option for the initial purchaser to buy up to $15 million more. (BioWorld Today) Read More

Partnering Profile Rising For All Of Asia, Especially China

Vion Raising $35.2M To Fund Triapine, Cloretazine Progress

U.S./Canadian, European Biotechnology VC Directories For 2004 Available

Vitex Proceeds With Financing To Raise $10.9M For Inactine

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Jan 30, 2025.

Today's news in brief

Briefs

BioWorld MedTech briefs for Jan. 30, 2026.

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

Centessa’s CNT-9982 shows promise for MDD

BioWorld Science

Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...

First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

BioWorld Science

Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...